TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06137144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3470
Description: AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
Study: NCT05444751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: Maintenance of general anesthesia: propofol infusion (50-150 μg.kg.min-1); ketamine infusion (up to 50 mg total); and inhaled anesthetic agent (isoflurane or sevoflurane) up to 0.5 MAC. N20 is not permitted.~Emergence from general anesthesia: N20 may be used during closure of the surgical incision to facilitate rapid emergence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA + ESP
Description: The choice of local anesthetic for spinal anesthesia will be confirmed after consultation with the attending surgeon to determine duration of surgery. For expected surgical times less than 90 minutes, up to 4 mL 1.5% mepivacaine (60 mg) will be used. Where the anticipated surgical duration is longer than 90 minutes, 2 mL 0.5% bupivacaine (10 mg) may be substituted. After patient (prone) positioning, maintenance of sedation will be achieved with a target RASS score of 0 to -1.~Propofol (25-50 μg.kg.min-1) and ketamine (up to 50 mg total dose) infusions will be titrated to effect. Intermittent boluses of propofol (10-20mg) may be used to achieve the desired sedation, as needed.~Patients will be offered to option of awake surgery, where no sedation will be provided, if preferred. Patients will be informed that at any time before or during the procedure, they may change their mind, and receive sedation.
Study: NCT05796349

Intervention type: DIAGNOSTIC_TEST
Intervention: multifrequency EIT-based for detecting intracranial abnormalities
Description: For subjects who received clinical trials, 16 electrodes were placed equidistantly in their head, and brain EIT data were measured at 9 frequencies in the range of 21 kHz to 100 kHz by applying a current RMS of 176 microamps.MFEIT image sequences were obtained according to certain imaging algorithms.

Intervention type: DIAGNOSTIC_TEST
Intervention: multifrequency EIT-based for detecting intracranial abnormalities
Description: For subjects who received clinical trials, 16 electrodes were placed equidistantly in their head, and brain EIT data were measured at 9 frequencies in the range of 21 kHz to 100 kHz by applying a current RMS of 176 microamps.MFEIT image sequences were obtained according to certain imaging algorithms.
Study: NCT05308667

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation (modified constraint-induced movement therapy)
Description: Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation (modified constraint-induced movement therapy)
Description: Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation (modified constraint-induced movement therapy)
Description: Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non-invasive brain stimulation (intermittent theta-burst stimulation)
Description: Intermittent theta-burst stimulation (iTBS): It is a form of repetitive transcranial magnetic stimulation and it increases the facilitation of the motor cortex.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-invasive brain stimulation (intermittent theta-burst stimulation)
Description: Intermittent theta-burst stimulation (iTBS): It is a form of repetitive transcranial magnetic stimulation and it increases the facilitation of the motor cortex.
Study: NCT04961827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-efficacy based images through instant messaging
Description: A total of 6 images will be sent to participants via instant messaging. Images will utilize concepts in the Theory of self-efficacy to increase dietary self-efficacy among participants and hence improve dietary quality beyond that of conventional nutrition counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Knowledge based images through instant messaging
Description: A total of 6 images will be sent to participants via instant messaging. Images will consist of information covered in nutrition counseling sessions, such as those related to serving sizes.
Study: NCT05645653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational tteaching
Description: A comprehensive assessment of adherence problems will be firstly conducted to identify the factors that affect adherence, including how and why these factors contribute to poor adherence. Medication-related knowledge and skills will be provided based on individual treatments and barriers to adherence. Motivational interviewing techniques will be used for a better understanding of patients' cognitive factors of adherence behavior.
Study: NCT06306352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrotactile feedback
Description: The ABLE exoskeleton is accompanied by a vibrotactile feedback belt which users wear around their chest to receive real-time feedback during the double support phase. This feedback can assist them in their weight shift during the double support phase.
Study: NCT05967208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONSORT referrals
Description: Participants will be offered SMS-based confidential social network referrals for HIV testing (CONSORT referrals) to extend to any of their social and sexual network contacts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Card referrals
Description: Participants will be offered physical invitation cards (card referrals) to extend to any of their social and sexual network contacts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Card referrals
Description: Participants will be offered physical invitation cards (card referrals) to extend to any of their social and sexual network contacts.
Study: NCT06403189

Intervention type: OTHER
Group type: OTHER
Intervention: Biologic samples and MRI
Description: * blood sample~* lumbar punction~* MRI
Study: NCT05435547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Will take Dexamethasone pre-operatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will take Placebo pre-operatively
Study: NCT05895838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will be allocated to intravenous administration of dexamethasonephosphate 20mg (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo at admission and again the following two mornings until discharge from ICU or a maximum of 3 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Patients will be allocated to intravenous administration of dexamethasonephosphate 20mg (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo at admission and again the following two mornings until discharge from ICU or a maximum of 3 doses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Backrest elevation
Description: Patients will be allocated to have their headrest positioned at 35 degrees backrest vs 5 degrees straight elevation of backrest for 72 hours (or until extubation if occuring prior to 72 hours).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Backrest elevation
Description: Patients will be allocated to have their headrest positioned at 35 degrees backrest vs 5 degrees straight elevation of backrest for 72 hours (or until extubation if occuring prior to 72 hours).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early wakeup call
Description: Patients will be allocated to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early wakeup call
Description: Patients will be allocated to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Patients will be allocated to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Patients will be allocated to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses.
Study: NCT05991323

Intervention type: DRUG
Intervention: Dupilumab
Description: Injection solution; subcutaneous
Study: NCT05847504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mSTARS
Description: mSTARS combines inpatient cognitive-behavioral skills training and outpatient use of a mobile app encouraging application of acquired skills to real life situations.
Study: NCT05932862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL309 (ISM3091)
Description: XL309 will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL309 (ISM3091)
Description: XL309 will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL309 (ISM3091)
Description: XL309 will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL309 (ISM3091)
Description: XL309 will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib administered orally twice daily.
Study: NCT04854772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Body Syndrome Therapy for Long Covid
Description: The intervention consists of a mind-body based intervention for the COVID long haul syndrome. The components of the intervention include knowledge therapy, desensitization, emotional expression, and stress reduction techniques.
Study: NCT05888805

Intervention type: OTHER
Group type: OTHER
Intervention: DIMS spectacle lens
Description: DIMS spectacle lens is a multifocal spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously.
Study: NCT04505358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-AD
Description: active vs placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: active vs placebo
Study: NCT05368350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-definition transcranial direct current stimulation (HD-tDCS)
Description: Other Names:~tDCS~1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with (1) Pre-SMA stimulation arm -- anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns or (2) LIFG stimulation arm -- at electrode F7 (International 10/10 System for electroencephalography electrode placement) and electrodes T7, FP1, AF3, and FC5 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-definition transcranial direct current stimulation (HD-tDCS)
Description: Other Names:~tDCS~1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with (1) Pre-SMA stimulation arm -- anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns or (2) LIFG stimulation arm -- at electrode F7 (International 10/10 System for electroencephalography electrode placement) and electrodes T7, FP1, AF3, and FC5 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
Study: NCT04853199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Each patient should receive one tablet twice a day 30 minutes before the meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo capsule contains 150 mg of microcrystalline cellulose and 1.5 mg of magnesium stearate.
Study: NCT05447871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided single injection modified 4 in 1 block technique
Description: A high-frequency ultrasound probe is placed over the femoral condyle and vastus medialis muscle is identified. The probe is slid proximally till the superficial femoral artery appeared. The probe is slid proximally till the descending genicular artery branching from the superficial femoral artery. The point of interest is 8-10 cm above the femoral condyle. The needle is guided into the Vastus medialis muscle till the nerve to Vastus medialis. At this point, 5-7 mL of the local anaesthetic drug is injected. The needle is guided further in-plane from lateral to medial side to reach the perivascular region and after negative aspiration 25 ml local anaesthetic drug is injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided adductor canal block technique
Description: The Adductor canal is identified in the middle of the thigh beneath the sartorius muscle using a high-frequency ultrasonic transducer. the probe is slid till the superficial femoral artery appeared in the adductor canal between vastus medialis and adductor longus muscle. A 22-gauge spinal needle is inserted in a lateral to medial plane to reach the perivascular region and after negative aspiration 20 ml local anaesthetic drug is injected, visualised to push the femoral artery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: bupivacaine 0.25%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Description: bupivacaine 0.25%
Study: NCT05826860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Practice
Description: Participants follow guided meditations in the Healthy Minds Program (HMP) mobile phone app for at least 15 min per day, for a total of 14 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling Workshop
Description: Participants attend 2 (90 min) workshops, teaching them creative writing tools and giving them opportunities to apply those tools.
Study: NCT06094231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic carbohydrate restriction combined with an SGLT-2-Inhibitor
Description: The patients will be educated on how to implement a therapeutic carbohydrate restriction, which consists of 50 to 130 grams of carbohydrate per day, simultaneously they will continue to receive the SGLT-2-Inhibitor dapagliflozin.
Study: NCT04843475

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Trans-thoracic Echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Trans-thoracic Echocardiography
Study: NCT02847013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP block w Liposomal bupivacaine
Description: TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block w normal saline
Description: TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)
Study: NCT06008743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Belt Accelerations
Description: Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control. The speed of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Belt accelerations combined with an exoskeleton
Description: Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control, and using a hip exoskeleton. The velocity of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg. At the same time, they will be interacting with a wearable motion assistive device (i.e., exoskeleton). The exoskeleton will apply forces to the leg to resist hip extension during accelerations, reducing hip extension relative to the values of that participant at baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable Stiffness treadmill
Description: Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with identical speed control. A variable stiffness mechanism under one belt will change the vertical stiffness of one side of the treadmill for one or multiple steps. The walkers will be informed before stepping on the softer surface on one side, which can be either the left or the right side.
Study: NCT06160505

Intervention type: DEVICE
Intervention: S53P4 Bioactive glass
Description: Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
Study: NCT04915482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined use of TPO-RAs with low-dose anti-CD20 antibody
Description: Experimental: Combined use of TPO-RAs with low-dose anti-CD20 antibody The starting dose of eltrombopag is 50-75mg once daily. The starting dose of hetrombopag is 5.0-7.5mg once daily. The starting dose of avatrombopag is 20-40mg once daily. Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a single dose of ortuzumab at 1000mg can be administered.. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The best available therapy
Description: The best available therapy except for combined use of TPO-RAs with low-dose anti-CD20 antibody includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists monotherapy, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
Study: NCT02826837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab
Description: The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)
Study: NCT05487118

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT + MCE
Description: Placebo PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, without any emission of therapeutic dose. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
Study: NCT05487118

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active PBMT + MCE
Description: Active PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, with a dose of 30 J per site. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
Study: NCT06440642

Intervention type: DEVICE
Intervention: tonopen
Description: Intraoculer pressure will be measured in the supine position after intubation (T1), during pneumoperitoneum (T2), when placed in steep trendelenburg posıtıon (T3), at the end of the operation when pneumoperitoneum is terminated (T4), after being placed back in the supine position (T5), and 10 minutes after being placed back in the supine position (T6).
Study: NCT05721560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair with the SINEFIX
Description: Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
Study: NCT05924126

Intervention type: OTHER
Intervention: empiric antibiotic therapy
Description: septic ICU patient given broad spectrum antibiotic therapy
Study: NCT04801641

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six placebo capsules taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: Titrated to two 0.5 mg capsules and four placebo capsules taken orally twice daily (Low-Dose) OR Titrated to six 0.5 mg capsules taken orally twice daily (High-Dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: Titrated to two 0.5 mg capsules and four placebo capsules taken orally twice daily (Low-Dose) OR Titrated to six 0.5 mg capsules taken orally twice daily (High-Dose)